Characteristics and Outcomes of Paroxysmal Sympathetic Hyperactivity in Anti-NMDAR Encephalitis

Abstract

BackgroundTo explore the clinical characteristics and prognosis of autonomic dysfunction and paroxysmal sympathetic hyperactivity (PSH), and evaluate the efficacy of drugs used to suppress PSH episode in anti-NMDAR encephalitis patients.MethodsPatients who met the diagnostic criteria of anti-NMDAR encephalitis were enrolled from January 2012 to August 2018 and followed up for 2 years. PSH was diagnosed according to the PSH-Assessment Measure. The demographics data, clinical features, auxiliary tests results, treatments, and outcomes were prospective collected and analyzed.ResultsA total of 132 anti-NMDAR encephalitis patients were enrolled, of which 27.3% and 9.1% experienced autonomic dysfunction and probable PSH respectively. Cardiac autonomic dysfunction was the most common subtype (77.8%). Patients with a higher incidence of ovarian teratoma, mechanical ventilation, neurological intensive care unit admission, and elevated glucose and NMDAR antibody titer in the CSF were more likely to exhibit autonomic dysfunction or PSH. Episodes of PSH can be suppressed by monotherapy in patients without prior sedative drug use with an efficacy of 90%. No significant difference was observed between the prognosis of patients with or without autonomic dysfunction, or between the PSH versus non-PSH groups after 6 months and even during long-term follow-up. However, patients with cardiac autonomic dysfunction had poor prognosis at 6 months.ConclusionPSH is a common clinical condition in patients with anti-NMDAR encephalitis, especially in severe cases, and can be effectively managed by several drug monotherapies. Despite necessitating longer hospital stay, autonomic dysfunction or PSH do not seem to compromise the neurological recovery of patients.

Paroxysmal sympathetic hyperexcitability after brain injury: A clinical analysis of case series

“…[ 10 ] Our study used PSH-AM to determine PSH, although PSH-AM may reduce the possibility of misdiagnosis, it also has a high sensitivity and low specificity and may overestimate the incidence of PSH. [ 14 ] Future studies will be required to clearly define the diagnostic criteria for PSH.…”

Status dystonicus in adult patients with anti-N-methyl-d-aspartate-acid receptor encephalitis

“…Other similarly presenting conditions such as paroxysmal sympathetic hyperactivity (PSH), neuroleptic malignant syndrome or serotonin syndrome, all of which can cause abnormal breathing, increased CK levels and hyperthermia [1] , also should be carefully discriminated. Nevertheless, it should be noted that SD, epilepsy, and PSH/autonomic dysfunction often coexist in critical anti-NMDAR encephalitis patients, making the diagnosis more complex and difficult [13] .…”

Thymic Hyperplasia-Associated Autoimmune Encephalitis Mimicking Neuroleptic Malignant Syndrome: A Case Report

“…A recent retrospective study of 24 patients with NMDA encephalitis found PSH in 50% of cases [ 7 ]. The prevalence was lower at 9% in a larger study involving 132 patients [ 8 ]. The most prominent features of PSH in this setting include tachycardia and hyperthermia.…”

“…PSH may be the result of injury to autonomic regulatory areas including the insular cortex, anterior cingulate and ventral prefrontal areas, amygdala, hypothalamus, and spinal cord. PSH can affect the duration of hospitalization but not mortality and functional outcome [ 8 ].…”